Recently, Finn et al. tested the combination of atezolizumab, a monoclonal antibody targeting PD-L1, plus bevacizumab, an anti-VEGF monoclonal antibody, as a front-line treatment of advanced HCC. The gene discussed is CD274; the disease is hepatocellular carcinoma.